Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Differences in Culture Prevent Tanabe, Taisho from Getting Together
December 17, 2001
- Chugai to Become Member of Roche Group
December 17, 2001
- BUSINESS NEWS IN BRIEF
December 17, 2001
- Actelion Sets Up Japanese Subsidiary with 2 ERAs: Dr Widmann
December 17, 2001
- Combined Sales of 12 Major Wholesalers Up 15.7%, Net Profits Down 50.2%
December 17, 2001
- Mean Price Discrepancy Rate Is 7.1%: Drug Price Survey
December 17, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
December 17, 2001
- Latest Proposals for NHI Price System Reform Explained
December 17, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 17, 2001
- Employees' Copayment to Be Raised to 30% "When Necessary"
December 17, 2001
- WORLD NEWS I N BRIEF
December 17, 2001
- Basic Policy for FY2002 Budget Approved
December 17, 2001
- 1st Large Epidemiologic Study on Arteriosclerotic Disease to Start in Japan
December 17, 2001
- Medical Fees to Be Reduced: The Question Is How Much
December 17, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
December 17, 2001
- Domestic Drug Production Down 1.7% to \6,18 Trillion in FY2000
December 17, 2001
- DIAGNOSTIC NEWS IN BRIEF
December 17, 2001
- 17th Quality Reevaluation to Start on 18 Mono-drugs, 8 Combinations
December 17, 2001
- Korosho to Regard Original Products without Generics as Long-listed
December 10, 2001
- Shimadzu: New Electronic Medical Chart System
December 10, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…